Skip to content
PICO Portalanswers from OpenAlex

P2.01-46 The Efficacy and Safety of 2nd-Line Nivolumab for Non-Small Cell Lung Cancer in Real-World Practice with Emphasis on Hyperprogession

PaperCitations, authors & open-access status

P2.01-46 The Efficacy and Safety of 2nd-Line Nivolumab for Non-Small Cell Lung Cancer in Real-World Practice with Emphasis on Hyperprogession is a paper indexed in PICO Portal from OpenAlex.

How many citations does P2.01-46 The Efficacy and Safety of 2nd-Line Nivolumab for Non-Small Cell Lung Cancer in Real-World Practice with Emphasis on Hyperprogession have?

PICO Portalcitation count

P2.01-46 The Efficacy and Safety of 2nd-Line Nivolumab for Non-Small Cell Lung Cancer in Real-World Practice with Emphasis on Hyperprogession has 2 citations in the OpenAlex counts PICO Portal stores.

When was P2.01-46 The Efficacy and Safety of 2nd-Line Nivolumab for Non-Small Cell Lung Cancer in Real-World Practice with Emphasis on Hyperprogession published?

PICO Portalyear

P2.01-46 The Efficacy and Safety of 2nd-Line Nivolumab for Non-Small Cell Lung Cancer in Real-World Practice with Emphasis on Hyperprogession has 2019 year in the PICO Portal index.

What is the open-access status of P2.01-46 The Efficacy and Safety of 2nd-Line Nivolumab for Non-Small Cell Lung Cancer in Real-World Practice with Emphasis on Hyperprogession?

PICO Portaloa status

P2.01-46 The Efficacy and Safety of 2nd-Line Nivolumab for Non-Small Cell Lung Cancer in Real-World Practice with Emphasis on Hyperprogession has bronze oa status in the PICO Portal index.

What is the DOI of P2.01-46 The Efficacy and Safety of 2nd-Line Nivolumab for Non-Small Cell Lung Cancer in Real-World Practice with Emphasis on Hyperprogession?

PICO Portaldoi

The DOI for P2.01-46 The Efficacy and Safety of 2nd-Line Nivolumab for Non-Small Cell Lung Cancer in Real-World Practice with Emphasis on Hyperprogession is on the source record.

What is the OpenAlex record for P2.01-46 The Efficacy and Safety of 2nd-Line Nivolumab for Non-Small Cell Lung Cancer in Real-World Practice with Emphasis on Hyperprogession?

PICO Portalopenalex

The OpenAlex for P2.01-46 The Efficacy and Safety of 2nd-Line Nivolumab for Non-Small Cell Lung Cancer in Real-World Practice with Emphasis on Hyperprogession is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial